Xenetic Biosciences, Inc.

Imagine a microscopic battlefield where your body’s first line of defense creates intricate, deadly traps. These are not science fiction, but a remarkable biological phenomenon called Neutrophil Extra

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Ikena Cuts Back As BMS Unravels Partner

Who: AbbVie/Calibr – Scripps Research Institute What: AbbVie and the institute’s drug discovery unit are building upon existing collaborations, giving the pharma option rights to new discovery targ

The progression of investigational products through a series of increasingly more sophisticated and targeted clinical trials is a well-tried and tested route for the development of new medicines for c